Coronavirus Scientific Advisory Board

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 16, 2023

JERUSALEM, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.

Key Points: 
  • - Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada -
    JERUSALEM, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.
  • Planning treatment of the first patient in the Canadian liver metastases safety and feasibility trial in Q4 2023 or Q1 2024.
  • As of September 30, 2023, the Company had cash, restricted cash, deposits and restricted deposits in the amount of $90.1 million, compared to $105.4 million on December 31, 2022.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Monday, November 13, 2023

“Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.

Key Points: 
  • “Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.
  • Financial Highlights for the Three Months Ended September 30, 2023
    Total revenues were $37.9 million in the third quarter of 2023, an 18% increase from the $32.2 million recorded in the third quarter of 2022.
  • S&M costs, for the third quarter of 2023 and 2022, included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Friday, November 10, 2023

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.

Key Points: 
  • In October 2023, Turnstone appointed Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board.
  • In July 2023, Turnstone priced its initial public offering (IPO) at $12.00 per share.
  • Cash, Cash Equivalents and Short-Term Investments: As of September 30, 2023, cash, cash equivalents and short-term investments were $109.1 million.
  • Net Loss: Net loss for the three months ended September 30, 2023, was $17.3 million, compared to net loss of $16.2 million for the third quarter of 2022.

Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders

Retrieved on: 
Wednesday, December 13, 2023

DLX-007 is a novel, first-in-class, neuroplastogen being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use.

Key Points: 
  • DLX-007 is a novel, first-in-class, neuroplastogen being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use.
  • "With nearly 110,000 people dying from drug overdoses in America last year, substance use disorders remain a critical public health issue with limited treatment options.
  • Preliminary data are being generated for its potential efficacy in treating substance use disorders with cocaine, amphetamines, and multiple substances.
  • Delix is rapidly advancing its library of thousands of novel compounds into scalable, orally-bioavailable, take-home therapies.

Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​

Retrieved on: 
Sunday, December 10, 2023

“We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.

Key Points: 
  • “We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.
  • Many people living with hemophilia B still experience bleeding episodes, irreversible joint damage and pain with current extended-release factor IX biologic therapy.
  • “Our goal is to create a new, potentially transformative treatment option that will provide people with hemophilia B the freedom to live a normal life, free of limitations from hemophilia B.
  • The data confirmed the expected biodistribution of FIX-expressing BCMs in bone marrow tissue, where they engraft stably over time.

PlumCare and Fabric Genomics Announce a Strategic Partnership to Integrate the Fabric AI Platform with PlumCare’s FirstSteps™ Newborn Genome Screening Program in Greece

Retrieved on: 
Thursday, December 7, 2023

PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece.

Key Points: 
  • PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece.
  • The goal of FirstSteps , a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.
  • View the full release here: https://www.businesswire.com/news/home/20231207013080/en/
    The FirstSteps program will leverage the power of the Fabric AI platform to offer rapid, accurate clinical genomic variant interpretation for whole genome sequencing (WGS) of screened newborns in Greece.
  • Fabric Genomics is proud to support the innovative PlumCare team to improve screening for babies in Greece by customizing its universal platform to the specific needs required in the national FirstSteps program.

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

Retrieved on: 
Wednesday, December 6, 2023

Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.

Key Points: 
  • Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.
  • “Delix is excited to share these data from DLX-001, the first novel neuroplastogen to enter clinical testing.
  • These data reinforce the potential of our broader neuroplastogen platform to develop therapies that can repair damaged neurons,” said Delix CEO Mark Rus.
  • I look forward to leveraging his considerable experiences as we progress our novel neuroplastogen platform and build Delix into a leading neuroscience company."

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Retrieved on: 
Wednesday, November 29, 2023

Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.

Key Points: 
  • Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.
  • As part of the next growth phase of the company, Paolo Michieli, PhD, (Founder and formerly Chief Scientific Officer) and Torsten Dreier, PhD, (previously Chief Development Officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB).
  • “Angelika’s extensive experience and deep knowledge as a senior drug developer will be of great value to the Board and our company.
  • Andrea Sáez was COO/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages.

BrainChip Announces Dr. Tony Lewis as the New Chief Technology Officer

Retrieved on: 
Tuesday, November 21, 2023

Tony has served as a visiting or adjunct professor at the University of Arizona, the University of Illinois, Urbana-Champaign, and the University of Waterloo.

Key Points: 
  • Tony has served as a visiting or adjunct professor at the University of Arizona, the University of Illinois, Urbana-Champaign, and the University of Waterloo.
  • His entrepreneurial experience is evident in his founding of a government funded R&D company specializing in neuromorphic computing and robotics.
  • Tony has also made his mark as a startup advisor and investor, bringing his technical acumen to various innovative ventures.
  • “While it is bitter-sweet, I’m also excited that with this seamless transition to Tony and his immense experience, we will further accelerate Akida’s technology pipeline to market.”

Therapeutic Solutions International Collaborates on Peer-Reviewed Publication on Personalized Immunotherapy for Brain Cancer Using mRNA

Retrieved on: 
Monday, November 20, 2023

Therapeutic Solutions International, Inc. (TSOI), announced today the publication of a peer-reviewed paper entitled “Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines” which appeared in the November 2023 issue of the Journal of Translational Medicine1.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today the publication of a peer-reviewed paper entitled “Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines” which appeared in the November 2023 issue of the Journal of Translational Medicine1.
  • The article was co-authored by Therapeutic Solutions International Board Member Dr. Thomas Ichim, Chief Scientific Officer Dr. Feng Lin, and Scientific Advisory Board Members Drs Santosh Kesari and Francesco Marincola.
  • In the publication, advances in stimulation of cancer-specific and patient-specific immunity to brain cancer are discussed, as well as methods of augmenting existing immunity.
  • The paper provides several explanations regarding the advantages of mRNA immunization, as well as discusses the means of integrating immunotherapy with other currently used approaches to brain cancer.